ONO-2808 / Ono Pharma - LARVOL DELTA

Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy (Ono Pharmaceuticals Press Release) - "In the exploratory interim analysis of this study, it was observed that the progression of MSA tended to be slower in the ONO-2808 group in terms of the clinical outcome endpoint, Unified Multiple System Atrophy Rating Scale (UMSARS). All doses were well tolerated with a manageable safety profile."

P2 data • Multiple System Atrophy

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy (clinicaltrials.gov) - P2 | N=92 | Active, not recruiting | Sponsor: Ono Pharmaceutical Co. Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Multiple System Atrophy

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Ono Pharmaceutical Co. Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Multiple System Atrophy

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Ono Pharmaceutical Co. Ltd

New P2 trial • CNS Disorders • Movement Disorders • Multiple System Atrophy

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants (clinicaltrials.gov) - P1; N=94; Completed; Sponsor: Ono Pharmaceutical Co. Ltd; Recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders